Vivek Subbiah, MD

home / authors / vivek-subbiah-md

Vivek Subbiah, MD, is the chief of early-phase drug development at Sarah Cannon Research Institute.

Articles

Oncology Experts Spotlight Breakthrough Therapies, AI-Driven Care at PCOC 2025

November 6th 2025

Oncology experts at PCOC 2025 discuss breakthrough therapies, AI-driven care, and evolving care delivery models shaping the future of oncology.

ESMO Congress Marks 50 Years by Showcasing the Future of Cancer Care: Vivek Subbiah, MD

October 15th 2025

Vivek Subbiah, MD, highlights key topics at the 50th European Society for Medical Oncology (ESMO) Congress, including the rise of tumor-agnostic therapies and the use of artificial intelligence (AI) in cancer care.

AI Should Support Clinicians, Not Replace Them: Vivek Subbiah, MD

October 10th 2025

Vivek Subbiah, MD, says artificial intelligence (AI) should assist clinicians in precision oncology, not replace human decision-making.

AI Expands Clinical Trial Access, Advances Drug Repurposing Efforts: Vivek Subbiah, MD

October 8th 2025

Artificial intelligence (AI) is expanding clinical trial access and enabling drug repurposing, according to Vivek Subbiah, MD.

Experts Highlight AI, Innovation, and Collaboration as Key PCOC Takeaways

October 2nd 2025

Five experts share their key takeaways from Patient-Centered Oncology Care® (PCOC) 2025, highlighting AI integration and collaboration to improve care.

AI, Genomic Testing Key to Advancing Precision Oncology: Vivek Subbiah, MD

October 1st 2025

Vivek Subbiah, MD, considers artificial intelligence (AI) and comprehensive somatic and germline testing essential for guiding precision oncology and improving patient care.

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777